ERBB2 and gastric cancer: Inroads in immunotherapy have yielded promising new agents on the horizon for gastric cancer treatment to complement the current armamentarium of surgery, chemotherapy, and radiation, and, more recently, multiple FDA-approved mAbs against vascular endothelial growth factor (VEGF, ramucirumab, 2014) and HER2/neu receptors (trastuzumab, 2010), which offer survival benefits in certain subgroups [80],[81].